Advertisement

AAPS PharmSciTech

, Volume 15, Issue 6, pp 1574–1587 | Cite as

High-Performing Dry Powder Inhalers of Paclitaxel DPPC/DPPG Lung Surfactant-Mimic Multifunctional Particles in Lung Cancer: Physicochemical Characterization, In Vitro Aerosol Dispersion, and Cellular Studies

  • Samantha A. Meenach
  • Kimberly W. Anderson
  • J. Zach Hilt
  • Ronald C. McGarry
  • Heidi M. MansourEmail author
Research Article Theme: Advances in Formulation and Device Technologies for Pulmonary Drug Delivery
Part of the following topical collections:
  1. Theme: Advances in Formulation and Device Technologies for Pulmonary Drug Delivery

Abstract

Inhalable lung surfactant-based carriers composed of synthetic phospholipids, dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylglycerol (DPPG), along with paclitaxel (PTX), were designed and optimized as respirable dry powders using organic solution co-spray-drying particle engineering design. These materials can be used to deliver and treat a wide variety of pulmonary diseases with this current work focusing on lung cancer. In particular, this is the first time dry powder lung surfactant-based particles have been developed and characterized for this purpose. Comprehensive physicochemical characterization was carried out to analyze the particle morphology, surface structure, solid-state transitions, amorphous character, residual water content, and phospholipid bilayer structure. The particle chemical composition was confirmed using attenuated total reflectance-Fourier-transform infrared (ATR-FTIR) spectroscopy. PTX loading was high, as quantified using UV-VIS spectroscopy, and sustained PTX release was measured over weeks. In vitro cellular characterization on lung cancer cells demonstrated the enhanced chemotherapeutic cytotoxic activity of paclitaxel from co-spray-dried DPPC/DPPG (co-SD DPPC/DPPG) lung surfactant-based carrier particles and the cytotoxicity of the particles via pulmonary cell viability analysis, fluorescent microscopy imaging, and transepithelial electrical resistance (TEER) testing at air-interface conditions. In vitro aerosol performance using a Next Generation Impactor™ (NGI™) showed measurable powder deposition on all stages of the NGI and was relatively high on the lower stages (nanometer aerodynamic size). Aerosol dispersion analysis of these high-performing DPIs showed mass median diameters (MMADs) that ranged from 1.9 to 2.3 μm with excellent aerosol dispersion performance as exemplified by high values of emitted dose, fine particle fractions, and respirable fractions.

Graphical Abstract

KEY WORDS

lung surfactant NBD-PC fluorescent microscopy imaging Next Generation Impactor (NGI) particle engineering design pulmonary cell lines 

Notes

Acknowledgments

The authors gratefully acknowledge financial support from the National Institutes of Health (NIH)-National Cancer Institute (NCI) Grant Number R25CA153954 and an NIH-NCI Cancer Nanotechnology Training Center (CNTC) Postdoctoral Traineeship awarded to SAM. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or the NIH. The authors thank Dr. Tonglei Li for XRPD and HSM access and Dr. J. Zach Hilt for ATR-FTIR access.

Conflict of Interest

No conflicts of interest exist.

References

  1. 1.
    American Cancer Society. Cancer Facts & Figures. In. Atlanta: American Cancer Society; 2013. p. 4–8.Google Scholar
  2. 2.
    Mansour HM, Rhee Y-S, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009;4:299–319.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Carvalho TC, Carbalho SR, McConville JT. Formulations for pulmonary administration of anticancer agents to treat lung malignancies. J Aerosol Med Pulm Drug Deliv. 2011;24(2):61–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, et al. Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv. 2008;21(1):61–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Sharma S, White D, Imondi A, Placke ME, Vail DM, Kris MG. Development of inhalation agents for oncologic use. J Clin Oncol. 2001;19(6):1839–47.PubMedGoogle Scholar
  6. 6.
    Gautam A. Targeted delivery of therapeutics by aerosol for cancer of the lung. Curr Cancer Drug Targets. 2003;3:57.CrossRefGoogle Scholar
  7. 7.
    Haigentz MJ, Perez-Soler R. Chemopreventative therapeutics: inhalation therapies for lung cancer and bronchial premalignancy. Meth Mol Med. 2003;75:771–80.Google Scholar
  8. 8.
    Rubin BK. Mucus and mucins. Otolaryngol Clin N Am. 2010;43(1):27.CrossRefGoogle Scholar
  9. 9.
    Laube BL, Janssens HM, de Jongh FHC, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about inhalation therapies. Eur Respir J. 2011;37:1308–31.PubMedCrossRefGoogle Scholar
  10. 10.
    Weers JG, Bell J, Chan HK, Cipolla D, Dunbar C, Hickey AJ, et al. Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23:S5–S23.PubMedCrossRefGoogle Scholar
  11. 11.
    Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulation in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:600–12.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24(3):411–37.PubMedCrossRefGoogle Scholar
  13. 13.
    Willis L, Hayes D, Mansour HM. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung. 2012;190(3):251–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Eldar-Boock A, Miller K, Sanchis J, Lupu R, Vicent MJ, Satchi-Fainaro R. Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials. 2011;32:3862–74.PubMedCrossRefGoogle Scholar
  15. 15.
    Gill KK, Nazzal S, Kaddoumi A. Paclitaxel-loaded PEG5000-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics and toxicological evaluation. Eur J Pharm Biopharm. 2011;79:276–84.PubMedCrossRefGoogle Scholar
  16. 16.
    Alipour S, Montaseri H, Tafaqhodi M. Preparation and characterization of biodegradable paclitaxel loaded alginate microparticles for pulmonary delivery. Colloids Surf B: Biointerfaces. 2010;81(2):521–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Mansour HM, Rhee YS, Park CW, DeLuca PP. Lipid nanoparticulate drug delivery and nanomedicine. In: Moghis A, editor. Lipids in nanotechnology. Urbana: American Oil Chemists Society (AOCS) Press; 2011. p. 221–68.Google Scholar
  18. 18.
    Jobe AH. Pulmonary surfactant therapy. N Engl J Med. 1993;328(12):861–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. J Clin Pharmacol. 2003;56:588–99.CrossRefGoogle Scholar
  20. 20.
    Forbes B, Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. Eur J Pharm Biopharm. 2005;60(2):193–205.PubMedCrossRefGoogle Scholar
  21. 21.
    Grainger CI, Greenwell LL, Lockley DJ, Martin GP, Forbes B. Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm Res. 2006;23(7):1482–90.PubMedCrossRefGoogle Scholar
  22. 22.
    Meenach SA, Anderson KW, Hilt JZ, McGarry RC, Mansour HM. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur J Pharm Sci. 2013;49(4):699–711.PubMedCrossRefGoogle Scholar
  23. 23.
    Meenach SA, Vogt FG, Anderson KW, Hilt JZ, McGarry RC, Mansour HM. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int J Nanomedicine. 2013;8:275–93.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Park CW, Li X, Vogt FG, Hayes DJ, Zwischenberger JB, Park ES, et al. Advanced spray dried design, physicochemical characterization and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. Int J Pharm. 2013;455(1–2):374–92.PubMedCrossRefGoogle Scholar
  25. 25.
    O’Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res. 2000;17(8):955–61.PubMedCrossRefGoogle Scholar
  26. 26.
    Sung JC, Padilla DJ, Garcia-Contreras L, VerBerkmoes JL, Durbin D, Peloquin CA, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res. 2009;26(8):1847–55.PubMedCrossRefGoogle Scholar
  27. 27.
    Salama RO, Traini D, Chan H-K, Young PM. Preparation and characterisation of controlled release co-spray dried drug–polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm. 2008;70:145–52.PubMedCrossRefGoogle Scholar
  28. 28.
    Son Y-J, McConville JT. Preparation of sustained release rifampicin microparticles for inhalation. J Pharm Pharmacol. 2012;64:1291–302.PubMedCrossRefGoogle Scholar
  29. 29.
    Son Y-J, McConville JT. Development of a standardized dissolution test method for inhaled pharmaceutical formulations. Int J Pharm. 2009;382:15–22.PubMedCrossRefGoogle Scholar
  30. 30.
    El-Sherbiny IM, McGill S, Smyth HDC. Swellable microparticles as carriers for sustained pulmonary drug delivery. J Pharm Sci. 2010;99(5):2343–56.PubMedGoogle Scholar
  31. 31.
    El-Sherbiny IM, Smyth HDC. Biodegradable nano-micro carrier systems for sustained pulmonary drug delivery: (I) self-assembled nanoparticles encapsulated in respirable/swellable semi-IPN microspheres. Int J Pharm. 2010;395:132–41.PubMedCrossRefGoogle Scholar
  32. 32.
    El-Sherbiny IM, Smyth HDC. Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles. Mol Pharm. 2012;9:269–80.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    <601> Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers monograph. In. USP 29-NF 24 The United States Pharmacopoeia and The National Formulary: The Official Compendia of Standards. Rockville, MD: The United States Pharmacopeial Convention, Inc.; 2006. p. 2617–2636.Google Scholar
  34. 34.
    Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol. 1998;85(2):379–85.PubMedGoogle Scholar
  35. 35.
    Finlay W. The ARLA respiratory deposition calculator. 2010. Available from: http://www.mece.ualberta.ca/arla/impactor_mmad_calculator.html.
  36. 36.
    Wu X, Hayes DJ, Zwischenberger JB, Kuhn RJ, Mansour HM. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. Drug Des Dev Ther. 2013;7:59–72.Google Scholar
  37. 37.
    Wu X, Zhang W, Hayes DJ, Mansour HM. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery. Int J Nanomedicine. 2013;8:1269–83.PubMedCentralPubMedGoogle Scholar
  38. 38.
    Mansour H, Wang DS, Chen CS, Zografi G. Comparison of bilayer and monolayer properties of phospholipid systems containing dipalmitoylphosphatidylglycerol and dipalmitoylphosphatidylinositol. Langmuir. 2001;17(21):6622–32.CrossRefGoogle Scholar
  39. 39.
    Alves GP, Santana MHA. Phospholipid dry powders produced by spray drying processing: structural, thermodynamic and physical properties. Powder Technol. 2004;145:139–48.CrossRefGoogle Scholar
  40. 40.
    Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Hitzman CJ, Elmquist WF, Wattenberg LW, Wiedmann TS. Development of a respirable, sustained release microcarrier of 5-fluorouracil I: in vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci. 2006;95(5):1114–26.PubMedCrossRefGoogle Scholar
  42. 42.
    Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25(12):563–70.PubMedCrossRefGoogle Scholar
  43. 43.
    Azarmi S, Roa WH, Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60:863–75.PubMedCrossRefGoogle Scholar
  44. 44.
    Hureaux J, Lagarce F, Gagnadoux F, Vecellio L, Clavreul A, Roger E, et al. Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur J Pharm Biopharm. 2009;73(2):239–46.PubMedCrossRefGoogle Scholar
  45. 45.
    Mansour HM, Zografi G. Relationships between equilibrium spreading pressure and phase equilibria of phospholipid bilayers and monolayers at the air-water interface. Langmuir. 2007;23:3809–19.PubMedCrossRefGoogle Scholar
  46. 46.
    Vehring R, Foss WR, Lechuga-Ballesteros D. Particle formation in spray drying. J Aerosol Sci. 2007;38(7):728–46.CrossRefGoogle Scholar
  47. 47.
    Hickey AJ, Mansour HM, Telko MJ, Xu Z, Smyth HDC, Mulder T, et al. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci. 2007;96(5):1282–301.PubMedCrossRefGoogle Scholar
  48. 48.
    Hickey AJ, Mansour HM, Telko MJ, Xu Z, Smyth HDC, Mulder T, et al. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics. J Pharm Sci. 2007;96(5):1302–19.PubMedCrossRefGoogle Scholar
  49. 49.
    Hickey AJ, Mansour HM. Delivery of drugs by the pulmonary route. In: Florence AT, Siepmann J, editors. Modern pharmaceutics. New York: Taylor and Francis; 2009. p. 191–219.Google Scholar
  50. 50.
    Edwards DA. The macrotransport of aerosol particles in the lung: aerosol deposition phenomena. J Aerosol Sci. 1995;26(2):293–317.CrossRefGoogle Scholar
  51. 51.
    Suarez S, Hickey AJ. Drug properties affecting aerosol behavior. Respir Care. 2000;45(6):652–66.PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2014

Authors and Affiliations

  • Samantha A. Meenach
    • 1
    • 2
  • Kimberly W. Anderson
    • 2
    • 3
  • J. Zach Hilt
    • 2
    • 3
  • Ronald C. McGarry
    • 4
  • Heidi M. Mansour
    • 5
    Email author
  1. 1.Drug Development Division, Department of Pharmaceutical Sciences, College of PharmacyUniversity of KentuckyLexingtonUSA
  2. 2.Department of Chemical and Materials Engineering, College of EngineeringUniversity of KentuckyLexingtonUSA
  3. 3.Center of Membrane SciencesUniversity of KentuckyLexingtonUSA
  4. 4.Department of Radiation Medicine, College of MedicineUniversity of KentuckyLexingtonUSA
  5. 5.Skaggs Pharmaceutical Sciences Center, College of PharmacyThe University of ArizonaTucsonUSA

Personalised recommendations